Employment and Operations - As of June 30, 2025, Nutex Health Inc. employed approximately 846 full-time employees and contracted 255 doctors, partnering with over 2,100 physicians within its networks[121]. - The company operates 24 hospital facilities across 11 states, implementing innovative healthcare models such as micro-hospitals and specialty hospitals[120]. - The population health management division includes a management services organization and operates under contracts with independent physician associations[126]. - The company plans to open three new hospital facilities by the end of 2025, which are currently under construction or in advanced planning stages[146]. - The company expects to launch one to three additional independent physician associations (IPAs) per year, primarily in areas surrounding existing micro-hospitals[146]. Revenue and Financial Performance - For the three months ended June 30, 2025, 97% of net patient service revenue was from insurance, compared to 93% for the same period in 2024, indicating a 4% increase in insurance revenue[129]. - The hospital division's revenue is primarily derived from federal agencies, private insurance carriers, and patients, with over 98% of net patient service revenue coming from non-patient third parties[128]. - In the hospital division, revenue for the three months ended June 30, 2025, was $236.3 million, compared to $67.6 million for the same period in 2024, representing a significant increase[160]. - Total revenue for the six months ended June 30, 2025, was $455.8 million, up from $143.5 million in the same period in 2024, indicating a growth of approximately 217%[161]. - Hospital Division revenue for the three months ended June 30, 2025 totaled $236.3 million, an increase of $168.7 million or 249.5% compared to $67.6 million for the same period in 2024[165]. - Hospital Division revenue for the six months ended June 30, 2025 totaled $440.2 million, an increase of $312.6 million or 244.9% compared to $127.6 million for the same period in 2024[180]. Profitability and Loss - The hospital division's gross profit for the three months ended June 30, 2025, was $125.6 million, compared to $22.8 million in the prior year, reflecting a substantial improvement[161]. - The population health management division reported a gross loss of $536,000 for the three months ended June 30, 2025, compared to a loss of $230,000 in the same period in 2024[161]. - Net loss attributable to Nutex Health Inc. increased to $3.5 million, or income of $0.60 per diluted share, for the six months ended June 30, 2025, compared to a net loss of $0.4 million, or loss of $0.07 per share, for the same period in 2024[178]. - The net income attributable to Nutex Health Inc. for the six months ended June 30, 2025, was a loss of $3.5 million, compared to a loss of $728,000 in the same period in 2024[161]. - Net loss attributable to Nutex Health Inc. decreased to $17.7 million, or loss of $2.95 per diluted share, for the three months ended June 30, 2025, compared to a net loss of $0.4 million, or loss of $0.07 per share, for the same period in 2024[162]. Adjusted EBITDA - The company reported an adjusted EBITDA of $144.4 million for the six months ended June 30, 2025, compared to $6.4 million in the same period in 2024[161]. - Adjusted EBITDA for the three months ended June 30, 2025 increased to $71.6 million from $6.8 million for the comparable period in 2024[163]. - Adjusted EBITDA for the three months ended June 30, 2025, was $71.6 million, a decrease from $78.3 million in the prior year[204]. Costs and Expenses - Corporate and other costs totaled $91.2 million for the three months ended June 30, 2025, an increase of 428.6% compared to $17.3 million for the same period in 2024[174]. - The total cost of arbitration for Nutex hospital and professional services was $48.0 million for the three months ended June 30, 2025, and $74.3 million for the six months ended June 30, 2025[145]. - Total finance lease payments for the six months ended June 30, 2025, amounted to $13.0 million, which should be deducted from EBITDA[204]. Cash and Financing - As of June 30, 2025, the company had $96.7 million of cash and equivalents, compared to $40.6 million as of December 31, 2024[194]. - As of June 30, 2025, the company had cash from operating activities of $78.2 million, primarily driven by significantly higher net income due to favorable developments in the arbitration process[202]. - The company had remaining availability of $4.1 million under outstanding lines of credit as of June 30, 2025[199]. - The company is currently working to supplement or replace smaller lines of credit with larger financing commitments, subject to market conditions[198]. - The company reported total repayments of lines of credit and notes payable of $6.0 million during the period[202]. Regulatory and Legal Matters - The No Surprises Act (NSA) was enacted to protect patients from surprise medical bills, establishing an IDR process for billing disputes between providers and insurers[130]. - The Independent Dispute Resolution (IDR) process is designed to take no more than 30 days, but in practice, it can take between three to five months for payment adjustments to be received[139]. - The company engaged HaloMD on July 1, 2024, to assist in challenging underpaid out-of-network claims, highlighting the complexity of the federal arbitration process[137]. Mergers and Acquisitions - The merger with Clinigence Holdings, Inc. was accounted for as a reverse business combination, with Nutex Health Holdco LLC treated as the accounting acquirer[119]. - The company made payments for acquisitions of businesses, net of cash acquired, totaling $2.6 million[202]. Shareholder Actions - On August 14, 2025, the Board authorized a stock repurchase program of up to $25.0 million to enhance shareholder value[151].

[Filing Information](index=1&type=section&id=Filing%20Information) This section provides essential administrative details regarding the Form 8-K filing, including registrant identity and securities information [General Information](index=1&type=section&id=General%20Information) This section provides the foundational details of the Form 8-K filing, including the registrant's identity, jurisdiction, and the date of the report - Registrant: **NUTEX HEALTH INC.**[2](index=2&type=chunk) - Date of Report (Date of earliest event reported): **October 20, 2025**[2](index=2&type=chunk) - State or Other Jurisdiction of Incorporation: **Delaware**[2](index=2&type=chunk) [Securities Information](index=1&type=section&id=Securities%20Information) This part details the company's registered securities and its status regarding emerging growth company provisions Securities Registered Pursuant to Section 12(b) of the Act | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.001 par value | NUTX | The NASDAQ Stock Market LLC | - The registrant is **not an emerging growth company**[4](index=4&type=chunk) [Current Report Items](index=2&type=section&id=Current%20Report%20Items) This section details significant events including preliminary financial results, a Nasdaq delisting notice, and a list of filed exhibits [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Nutex Health Inc. issued a press release on October 20, 2025, providing anticipated preliminary financial metrics for the quarter ended September 30, 2025. This information is furnished, not filed, under SEC regulations - On **October 20, 2025**, Nutex Health Inc. issued a press release (Exhibit 99.1) containing anticipated preliminary financial metrics for the period ended **September 30, 2025**[5](index=5&type=chunk) - The information furnished in this Item 2.02 and Exhibit 99.1 is **not deemed 'filed'** for purposes of Section 18 of the Securities Exchange Act of 1934[6](index=6&type=chunk) [Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](index=2&type=section&id=Item%203.01%20Notice%20of%20Delisting%20or%20Failure%20to%20Satisfy%20a%20Continued%20Listing%20Rule%20or%20Standard%3B%20Transfer%20of%20Listing) The Company received a Nasdaq notice of non-compliance due to the late filing of its June 30, 2025 Form 10-Q. Nutex Health submitted a compliance plan and was granted an extension until December 12, 2025, to rectify the filing deficiency - On **August 20, 2025**, the Company received a notice from Nasdaq for non-compliance with Listing Rule 5250(c)(1) due to the failure to timely file its Quarterly Report on Form 10-Q for the period ended **June 30, 2025**[7](index=7&type=chunk) - The Company submitted a plan to Nasdaq on **October 15, 2025**, to regain compliance and requested an extension until **December 12, 2025**[8](index=8&type=chunk) - Nasdaq granted the extension request on **October 16, 2025**; failure to file the Form 10-Q by **December 12, 2025**, will result in a delisting notice[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits included with the Form 8-K filing, specifically identifying the press release mentioned in Item 2.02 Exhibits | Exhibit No. | Description of Exhibit | | :---------- | :--------------------------- | | 99.1 | Press Release dated October 20, 2025 | [Signature](index=3&type=section&id=Signature) This section confirms the official signing and submission of the report by the company's Chief Financial Officer [Report Signature](index=3&type=section&id=Report%20Signature) The report was officially signed by the Chief Financial Officer of Nutex Health Inc., confirming its submission - The report was signed on behalf of **NUTEX HEALTH INC.** by **Jon C. Bates**, Chief Financial Officer[12](index=12&type=chunk) - Date of signature: **October 20, 2025**[12](index=12&type=chunk)

Revenue and Income - Total revenue for the first quarter of fiscal 2026 was $14,883 million, an increase of 8% compared to $13,841 million in the same period last year[170]. - Net income for the quarter was $2,860 million, a 5% increase from $2,711 million, with diluted earnings per share rising by 6% to $0.72[170]. - Operating income rose by 43% to $3,363 million in Q1 FY2026, with operating income as a percentage of revenue increasing to 22.6% from 17.0%[239]. Revenue Breakdown - Product revenue increased by 10%, while services revenue grew by 2%, with total software revenue reaching $5.7 billion, up 3%[173]. - Revenue from the Americas increased by $0.7 billion, while EMEA and APJC revenues rose by $0.2 billion and $0.1 billion, respectively[175]. - Product revenue increased by 10% to $11,077 million, while services revenue grew by 2% to $3,806 million[202][204]. - Revenue from the Americas segment was $8,989 million, representing a 9% increase, with product revenue in this segment rising by 12% to $6,706 million[203][208]. - EMEA segment revenue increased by 5% to $3,784 million, with product revenue growing by 6% to $2,846 million[203][209]. - APJC segment revenue rose by 5% to $2,111 million, with product revenue increasing by 7% to $1,525 million[203][210]. Product Performance - Networking product revenue increased by 15% to $7,768 million, driven by growth in Service Provider Routing and AI Infrastructure solutions[212][213]. - Security product revenue decreased by 2% to $1,980 million, impacted by a shift from on-premise deals to cloud subscriptions[212][214]. - Collaboration product revenue declined by 3% to $1,055 million, primarily due to decreases in Devices and Webex Suite offerings[212][215]. Expenses and Margins - Operating income as a percentage of revenue improved by 5.6 percentage points to 22.6% due to lower restructuring charges and revenue growth[174]. - Research and development expenses were $2,400 million, up 5% from $2,286 million, reflecting continued investment in innovation[170]. - The gross margin percentage decreased by 0.4 percentage points to 65.5%, primarily due to product mix and pricing impacts[170]. - Product gross margin decreased to 64.5% in Q1 FY2026 from 65.1% in Q1 FY2025, primarily due to negative impacts from product mix and pricing[221]. - Services gross margin increased by 0.4 percentage points to 68.4% in Q1 FY2026, driven by cost efficiencies[225]. - Total gross margin for the company was 65.5% in Q1 FY2026, down from 65.9% in Q1 FY2025, with total gross margin amounting to $9,745 million compared to $9,121 million[227]. Cash Flow and Investments - Total cash and cash equivalents and investments stood at $15,736 million, a slight decrease from $16,110 million[178]. - Free cash flow for the three months ended October 25, 2025, was $2,889 million, a decrease of approximately 16% from $3,444 million for the same period in 2024[250]. - Cash returned to stockholders included $1.6 billion in dividends and $2.0 billion in stock repurchases, contributing to a net decrease in cash and cash equivalents and investments of $374 million[247]. Tax and Compliance - The effective tax rate for the first quarter of fiscal 2026 was a tax provision of 15.7%, compared to a benefit of 19.6% in the first quarter of fiscal 2025[198]. - The effective tax rate for Q1 FY2026 was 15.7%, up from (19.6)% in Q1 FY2025, primarily due to a prior year tax benefit of $720 million[244]. - The company was in compliance with all debt covenants as of October 25, 2025[266]. Future Outlook and Commitments - The company plans to continue investing in key priority areas to drive long-term profitable growth amid a competitive environment[176]. - The company expects to continue entering into additional purchase commitments in FY2026, increasing supply chain exposure[224]. - The remaining authorized amount for stock repurchases is approximately $12.2 billion, with no termination date[253]. Performance Obligations and Deferred Revenue - Remaining performance obligations totaled $42,873 million, down from $43,533 million[178]. - Total remaining performance obligations as of October 25, 2025, decreased by 2% to $42.873 billion compared to the end of fiscal 2025[270]. - Total deferred revenue decreased by 3% to $27.969 billion, with deferred product revenue down 2% and deferred services revenue down 4%[271].

Financial Performance - Revenues for Q4 2025 totaled $298 million, an increase of 8% compared to $275.1 million in Q4 2024[3] - Gross profit for Q4 2025 was $94 million, or 31.4% of revenue, representing a 16% increase from $80.4 million, or 29.2% of revenue, in Q4 2024[7] - Net income for Q4 2025 reached $51 million, or $4.22 per diluted share, up 12% from $46.1 million, or $3.77 per diluted share, in Q4 2024[10] - Full year revenues for Fiscal 2025 were $1.1 billion, a 9% increase from $1.0 billion in Fiscal 2024[11] - Full year gross profit for Fiscal 2025 was $324 million, or 29.4% of revenues, up 19% from $273.1 million, or 27.0% of revenues, in Fiscal 2024[12] - Full year net income for Fiscal 2025 was $181 million, or $14.86 per diluted share, a 21% increase from $149.8 million, or $12.29 per diluted share, in Fiscal 2024[13] Orders and Backlog - New orders in Q4 2025 totaled $271 million, a 1% increase from $267 million in Q4 2024[9] - Backlog as of September 30, 2025, was $1.4 billion, an increase of 3% compared to $1.36 billion as of September 30, 2024[9] Strategic Developments - The acquisition of Remsdaq Ltd. was completed, enhancing Powell's capabilities in electrical automation solutions[3] - The company expects continued strong order activity and a sustainable margin profile entering Fiscal 2026, despite typical seasonality in Q1[16]

Financial Performance - Solana Company reported third quarter revenue of $697,000, including first-time staking rewards income of $342,000[4] - Total operating expenses for the third quarter of 2025 were $36.0 million, compared to $3.9 million in the prior year period[6] - The net loss for the third quarter of 2025 was $352.8 million, or a loss of $32.89 per basic and diluted common share, compared to a net loss of $3.7 million in the prior-year period[10] Capital and Funding - The company closed a $508 million PIPE transaction on September 18, 2025, and launched an ATM program to raise additional capital[4][7] - Cash and liquidity as of September 30, 2025, included $124 million in cash and $350.2 million of digital assets at fair value, totaling $474.2 million[11] Expenses - Selling, general and administrative expenses increased to $4.6 million from $2.9 million in the prior year, primarily due to a $1.5 million discretionary bonus[5] - Research and development expenses decreased to $0.9 million from $1.1 million in the prior year, driven by reduced clinical trial activities[5] Asset Valuation - An unrealized loss on digital assets of $30.5 million was recorded due to the net change in fair value of digital assets held by the company[5] Product Development - The company announced positive clinical data for the PoNS device, demonstrating its effectiveness in improving gait deficits[7] Strategic Goals - Solana Company aims to maximize SOL per share through strategic use of capital markets and on-chain opportunities[13]

Financial Performance - Consolidated sales increased by $1.5 million, or 0.3%, in the second quarter of fiscal 2026 compared to the same period last year, while sales decreased by $1.9 million, or 0.2%, in the first six months[109]. - Operating income for the second quarter of fiscal 2026 was $36,179,000, a decrease of 6.7% from $38,772,000 in the same quarter of fiscal 2025[108]. - The operating margin decreased to 6.9% in the second quarter of fiscal 2026 from 7.4% in the same quarter of fiscal 2025[108]. - Gross margin decreased by 10 basis points in the second quarter of fiscal 2026 compared to the same period last year, driven by increased supply chain costs[112]. - SG&A expenses as a percentage of sales increased by 40 basis points in the second quarter of fiscal 2026 due to fixed cost deleverage in the Retail segment[112]. - Retail segment sales increased by $0.5 million, or 0.2%, in Q2 2026, and by $5.3 million, or 1.2%, in the first six months compared to the same periods last year[114]. - Wholesale segment sales rose by $5.5 million, or 2%, in Q2 2026, and by $7.6 million, or 1%, in the first six months compared to the same periods last year[118]. - Operating income for the Retail segment decreased by 14.6% in Q2 2026 and by 23.9% in the first six months compared to the same periods last year[114]. - Operating margin for the Retail segment fell by 190 basis points in Q2 2026 and by 290 basis points in the first six months compared to the same periods last year[116]. - Gross margin for the Wholesale segment increased by 100 basis points in Q2 2026 and by 40 basis points in the first six months compared to the same periods last year[119]. - Corporate and Other sales decreased by $3.4 million, or 8.1%, in Q2 2026, and by $10.9 million, or 13.5%, in the first six months compared to the same periods last year[122]. Cash Flow and Investments - Net cash provided by operating activities was $86.3 million in the first six months of fiscal 2026, an increase of $18.1 million compared to the same period last year[132]. - Capital expenditures in the first six months of fiscal 2026 were $38.9 million, primarily related to new stores and manufacturing investments[134]. - Cash and cash equivalents increased to $338.5 million as of October 25, 2025, compared to $328.4 million at April 26, 2025[130]. - Cash paid to shareholders in quarterly dividends was $18.1 million, with expectations for regular quarterly dividends to continue[143]. - Cash used to repurchase 0.3 million shares of company stock amounted to $13.3 million, with 3.4 million shares remaining available for repurchase as of October 25, 2025[143]. - Cash paid for tax withholding on stock issued as part of employee benefit plans was $4.9 million, net of proceeds from exercised stock options[143]. Strategic Initiatives - The company aims to grow sales and market share through its Century Vision strategic plan, targeting its centennial year in 2027[100]. - The company plans to expand its retail store network and upgrade existing locations to new concept designs to drive growth in the Retail segment[106]. - The La-Z-Boy Stores retail network consists of 370 stores, over 500 La-Z-Boy Comfort Studio locations, and over 800 La-Z-Boy branded space locations[102]. - Joybird operates 14 small-format stores and focuses on a digital-first consumer experience to drive profitable growth[103]. - The company has approximately 7.7 million square feet of proprietary floor space dedicated to selling La-Z-Boy branded products in North America[102]. Tax and Accounting - The effective tax rate was 26.7% for Q2 2026 and 26.1% for the first six months, compared to 26.3% and 25.9% for the same periods last year[128]. - There were no material changes to critical accounting policies during the six months ended October 25, 2025[144]. - Recent accounting standards and their impacts were discussed in the Quarterly Report on Form 10-Q[145]. - No material changes in market risk disclosures were noted during the first six months of fiscal 2026[146].

Sales Performance - Total sales for the second quarter reached $522 million, a slight increase of 0.3% compared to the prior year[3] - Retail segment written sales grew by 4%, while same-store sales decreased by 2%, indicating sequential improvement over the last two quarters[4] - Fiscal third quarter sales are expected to be between $525 million and $545 million, reflecting a year-over-year growth of 1-4%[6] - Consolidated sales for the quarter ended October 25, 2025, were $522.48 million, slightly up from $521.03 million in the same quarter last year, representing a 0.3% increase[27] - The wholesale segment reported sales of $369.44 million, up from $363.90 million, a 1.4% increase year-over-year[33] - The retail segment sales remained relatively stable at $222.04 million compared to $221.56 million in the previous year, reflecting a slight increase of 0.2%[33] Profitability Metrics - GAAP operating margin was 6.9%, down from 7.4% in the prior year, while adjusted operating margin was 7.1%, down from 7.5%[12] - Diluted earnings per share (EPS) were $0.70 on a GAAP basis and $0.71 on an adjusted basis, compared to $0.71 in the prior year[12] - Operating income decreased to $36.18 million for the quarter, down 6.7% from $38.77 million in the same quarter last year[27] - Net income attributable to La-Z-Boy Incorporated for the quarter was $28.86 million, a decrease of 3.9% from $30.04 million in the prior year[27] - Diluted net income per share was $0.70, compared to $0.71 in the same quarter last year, reflecting a decline of 1.4%[27] - Adjusted net income attributable to La-Z-Boy Incorporated for the six months ended October 25, 2025, was $48,892, down from $56,678 in the prior year, representing a decrease of approximately 13%[34] Cash Flow and Assets - Generated $50 million in operating cash flow for the quarter, which is three times the amount from the same period last year[4] - Total current assets increased to $823.26 million from $805.69 million, marking a growth of 2.2%[29] - Total assets rose to $1.96 billion, up from $1.92 billion, indicating a 1.9% increase[29] - Cash and cash equivalents at the end of the period were $338.51 million, up from $328.45 million, showing a growth of 0.3%[31] Segment Performance - The wholesale segment reported an operating income of $29,056 for the quarter, which is 7.9% of sales, compared to $24,529 (6.7% of sales) in the same quarter last year[38] - The retail segment's operating income decreased to $23,821 (10.7% of sales) from $27,897 (12.6% of sales) year-over-year[38] - The corporate and other segment reported an operating loss of $16,698 for the quarter, compared to a loss of $13,654 in the same quarter last year[38] Strategic Initiatives - Announced a 10% increase in quarterly dividend to $0.242, marking the fifth consecutive year of double-digit increases[4] - Completed a 15-store acquisition in the southeast U.S., expected to add approximately $80 million in annual retail sales[4] - Plans to exit non-core businesses and proposed closure of the UK manufacturing facility, which will reduce sales by approximately $30 million net[4] Other Financial Metrics - Gross profit for the quarter was $231.14 million, compared to $230.65 million in the prior year, indicating a marginal increase of 0.2%[27] - GAAP gross profit for the quarter ended October 25, 2025, was $231,138, compared to $230,648 for the same quarter last year, reflecting a slight increase[34] - Adjusted gross profit for the six months ended October 25, 2025, was $442,412, slightly down from $444,131 in the prior year[34] - The company incurred distribution transformation charges of $768 in the current quarter, compared to no charges in the same quarter last year[34]

Financial Performance - Cambium Networks Corporation announced an update on recent financial and commercial activity on November 18, 2025[6] - The financial results and operational updates are detailed in Exhibit 99.1 of the report[7] Market Conditions - The press release includes forward-looking statements regarding the company's performance and market conditions[6] - The report emphasizes caution regarding factors that could cause actual results to differ from anticipated outcomes[6] Company Information - The company is listed on the Nasdaq Global Market under the symbol CMBM[5]

Financial Performance - For the three months ended September 30, 2025, the company reported a net loss of $341,897, with operating costs of $428,114 and a gain on investments held in the Trust Account of $119,784[143]. - For the nine months ended September 30, 2025, the company had a net loss of $863,650, resulting from operating costs of $1,150,604 and a gain on investments held in the Trust Account of $370,226[145]. - The company incurred net cash used in operating activities of $1,041,916 for the nine months ended September 30, 2025, due to the net loss and changes in working capital[147]. Capital and Funding - The company generated gross proceeds of $115,000,000 from the Initial Public Offering of 11,500,000 units on May 9, 2023[150]. - As of September 30, 2025, the company had $319,258 in cash and cash equivalents held outside of the Trust Account and a working capital deficit of $3,049,242[152]. - The company has deferred underwriting fees of $5,175,000 and up to $1,710,000 in promissory notes due upon the completion of its business combination[158]. Business Operations - The company has not engaged in any operations or generated revenues to date, focusing solely on financing and organizational activities[142]. - The company has not entered into any off-balance sheet financing arrangements as of September 30, 2025[159]. Future Plans - The company has until September 9, 2026, to complete a business combination, with the possibility of monthly extensions thereafter[155]. - The company plans to address its liquidity concerns through the successful closing of a business combination[153].

Financial Results - KULR Technology Group, Inc. announced financial results for Q3 2025, with specific figures to be detailed in the press release[5] - The report was filed on November 18, 2025, indicating the date of the earliest event reported[2] - The press release is attached as Exhibit 99.1, providing detailed financial data and insights[11] Company Information - The company is listed on NYSE American LLC under the trading symbol KULR[3] - KULR Technology Group is classified as an emerging growth company, which may influence its financial reporting standards[4] - The company’s principal executive offices are located in Webster, Texas[2] Operational Highlights - The press release includes recent operational highlights, which may impact future performance[7] - The financial results and operational updates are not deemed "filed" under the Securities Exchange Act, indicating a specific regulatory compliance approach[10] Investor Communication - The company utilizes various social media channels for public disclosures, enhancing investor communication[9] - The report emphasizes the importance of reviewing the company's website and social media for material information updates[9]